"According to The Verge, health providers writing Google reviews about patients with identifiable information is a HIPAA violation," writes Slashdot reader August Oleman. From the report: In the past few years, the phrase 'HIPAA violation' has been thrown around a lot, often incorrectly. People have cited the law, which protects patient health information, as a reason they can't be asked if they're vaccinated or get a doctor's note for an employer. But asking someone if they're vaccinated isn't actually a HIPAA violation. That's a fine and not-illegal thing for one non-doctor to ask another non-doctor. What is a HIPAA violation is what U. Phillip Igbinadolor, a dentist in North Carolina, did in September 2015, according to the Department of Health and Human Services. After a patient left an anonymous, negative Google review, he logged on and responded with his own post on the Google page, saying that the patient missed scheduled appointments. [...]

In the post, he used the patient's full name and described, in detail, the specific dental problem he was in for: "excruciating pain" from the lower left quadrant, which resulted in a referral for a root canal. That's what a HIPAA violation actually looks like. The law says that healthcare providers and insurance companies can't share identifiable, personal information without a patient's consent. In this case, the dentist (a healthcare provider) publicly shared a patient's name, medical condition, and medical history (personal information). As a result, the office was fined $50,000 (PDF).

In the past five years, reports of staggering insect declines have stoked anxiety and debate concerning the fate of the "little things that run the world," as the late biologist E. O. Wilson once called them. As for the how and why of these declines, the prime culprits are habitat destruction, rampant use of pesticides, and climate change. But new research published March 30 in Biology Letters adds an unexpected suspect, at least for a large swath of North America: the earthworm. From a report: The study looked at 60 plots in an aspen and poplar forest in Alberta, Canada, and found that as the numbers of earthworms wriggling in the soil and leaf litter increased, the diversity and abundance of invertebrates aboveground decreased. These results might sound surprising, since earthworms are widely considered to be helpful garden residents. Worms earned their reputation by aerating and mixing soil with their burrows and releasing locked up nutrients in their castings, all of which can help certain plants thrive.

But this new study is part of a growing body of research suggesting that at least in the forests of northern North America, earthworms may not be the slimy angels of the underworld we tend to think they are. "When people talk about insect decline, they rarely talk about the soil," says Nico Eisenhauer, a soil ecologist at Leipzig University in Germany and one of the authors of the new study. "Many of the insects and invertebrates that are in decline have life phases in the soil. What you don't see flying around now has first disappeared from the soil, and earthworms can fundamentally alter soil conditions."

Earthworms' subterranean engineering isn't a problem in their native ecosystems, but in the northern half of North America, the glaciers of the last ice age wiped out virtually all soil-dwelling worms more than 10,000 years ago. The ice sheets covered nearly all of Canada, most of the northeast U.S., and much of the upper Midwest. When the ice receded, forests returned but the worms did not because they can only expand their range by a maximum of about 30 feet a year. These northerly ecosystems evolved for millennia in the absence of earthworms. Without worms munching through fallen foliage and churning the soil, these forests accumulated thick layers of leaf litter, which came to support a vast array of animals, fungi, and plants. Eisenhauer says even non-scientists can appreciate the difference.

Genetic testing to predict how individuals will respond to common medicines should be implemented without delay to reduce the risk of side-effects and ensure that everyone is given the right drug at the right dose, experts have said. From a report: About 6.5% of UK hospital admissions are caused by adverse drug reactions, while most prescription medicines only work on 30% to 50% of people. A significant part of this is due to genetics: almost 99% of people carry at least one genetic variation that affects their response to certain drugs, including commonly prescribed painkillers, heart disease drugs and antidepressants. By the age of 70, about 90% of people are taking at least one of these medications.

A new report, published by the British Pharmacological Society and the Royal College of Physicians, argues that many of these issues could be addressed through pharmacogenomic testing, which allows personalised prescribing according to people's genes. "The ultimate goal is to make pharmacogenomic prescribing a reality for everyone within the NHS, which will empower healthcare professionals to deliver better, more personalised care," said Sir Munir Pirmohamed, a professor of pharmacology and therapeutics at the University of Liverpool, who chaired the report's working party. "The aim of pharmacogenomics is to make sure patients get the right drug, at the right dose, at the right time to be able to improve their outcomes, treat their symptoms, cure their disease and prevent side-effects."

sciencehabit shares a report from Science.org: Addition and subtraction must be hard for fish, especially because they don't have fingers to count on. But they can do it -- albeit with small numbers -- a new study reveals. By training the animals to use blue and yellow colors as codes for the commands "add one" and "subtract one," respectively, researchers showed fish have the capacity for simple arithmetic.

To make the find, researchers at the University of Bonn adopted the design of a similar experiment conducted in bees. They focused on bony cichlids (Pseudotropheus zebra) and cartilaginous stingrays (Potamotrygon motoro), which the lab uses to study fish cognition. In the training phase, the scientists showed a fish in a tank an image of up to five squares, circles, and triangles that were all either blue or yellow. The animals had 5 seconds to memorize the number and color of the shapes; then a gate opened, and the fish had to choose between two doors: one with an additional shape and the other with one fewer shape.

The rules were simple: If the shapes in the original image were blue, head for the door with one extra shape; if they were yellow, go for the door with one fewer. Choosing the correct door earned the fish a food reward: pellets for cichlids, and earthworms, shrimp, or mussels for stingrays. Only six of the eight cichlids and four of the eight stingrays successfully completed their training. But those that made it through testing performed well above chance, the researchers report today in Scientific Reports.

An anonymous reader quotes a report from the Guardian: More than two decades after the draft human genome was celebrated as a scientific milestone, scientists have finally finished the job. The first complete, gap-free sequence of a human genome has been published in an advance expected to pave the way for new insights into health and what makes our species unique. Until now, about 8% of the human genome was missing, including large stretches of highly repetitive sequences, sometimes described as "junk DNA." In reality though, these repeated sections were omitted due to technical difficulties in sequencing them, rather than pure lack of interest.

Sequencing a genome is something like slicing up a book into snippets of text then trying to reconstruct the book by piecing them together again. Stretches of text that contain a lot of common or repeated words and phrases would be harder to put in their correct place than more unique pieces of text. New "long-read" sequencing techniques that decode big chunks of DNA at once -- enough to capture many repeats -- helped overcome this hurdle. Scientists were able to simplify the puzzle further by using an unusual cell type that only contains DNA inherited from the father (most cells in the body contain two genomes -- one from each parent). Together these two advances allowed them to decode the more than 3 billion letters that comprise the human genome. The science behind the sequencing effort and some initial analysis of the new genome regions are outlined in six papers published in the journal Science.

Despite the United States and Russia's deteriorating relationship here on Earth, Russia is still considering extending its participation on the International Space Station through 2030, according to NASA. However, it could be a few months before there is a solid update on Russia's official stance. From a report: NASA and Russia's state space corporation, Roscosmos, have been the two largest partners on the International Space Station for the last three decades. The two organizations have agreed to work together on the ISS through 2024, but at the end of last year, the Biden administration announced its intentions to extend the space station program through 2030. Russia has not formally agreed to the extension yet.

Roscosmos's participation in the extension started to seem unlikely after Russia invaded Ukraine in February. In response to the war, the United States sanctioned Russia's major industries, which triggered outrage from the head of Roscosmos, Dmitry Rogozin. On Twitter, Rogozin made wild threats about the future of the ISS, insinuating that the station could come crashing down on the United States if Russia withdrew prematurely from the program. He has also hinted at revisiting the partnership with the US in light of the sanctions.

The Hubble Space Telescope has glimpsed the most distant single star it's ever observed, glimmering 28 billion light-years away. And the star could be between 50 to 500 times more massive than our sun, and millions of times brighter. From a report: It's the farthest detection of a star yet, from 900 million years after the big bang. Astronomers have nicknamed the star Earendel, derived from an Old English words that means "morning star" or "rising light." A study detailing the findings published Wednesday in the journal Nature. This observation breaks the record set by Hubble in 2018 when it observed a star that existed when the universe was around four billion years old. Earendel is so distant that the starlight has taken 12.9 billion years to reach us. This observation of Earendel could help astronomers to investigate the early years of the universe.

"As we peer into the cosmos, we also look back in time, so these extreme high-resolution observations allow us to understand the building blocks of some of the very first galaxies," said study coauthor Victoria Strait, a postdoctoral research at the Cosmic Dawn Center in Copenhagen, in a statement. "When the light that we see from Earendel was emitted, the Universe was less than a billion years old; only 6% of its current age. At that time it was 4 billion lightyears away from the proto-Milky Way, but during the almost 13 billion years it took the light to reach us, the Universe has expanded so that it is now a staggering 28 billion lightyears away."

"Following up on a 2020 submission, more samples and hi-res data have been added to NASA's research-grade Astromaterials 3D site," writes Slashdot reader White Yeti. "I don't see a new/news link, so here's text from the informal release statement." From the release: Astromaterials 3D, the first virtual library of NASA's collections of Apollo Lunar and Antarctic Meteorite samples, is releasing 20 new lunar and meteorite samples to the public this month! This launch also includes the release of an exciting new feature, called NASA Pins, which allows the public to view pre-selected sample characteristics on each rock's surface and within the XCT imagery, in order to share the incredible science these space rocks reveal. Each NASA Pin is curated by NASA Scientists and includes brief explanations about each pinned feature. This launch also includes the highly anticipated public release of the actual high-resolution OBJ files that the Astromaterials 3D team creates for each rock, easily and freely downloadable from every rock's page. Originally launched to the public in December 2020, the Astromaterials 3D Website and Explorer Application continues to grow, offering a dynamic, interactive, and information-rich visualization tool for researchers and the general public. Keep your eye on the site for this exciting forthcoming release: https://ares.jsc.nasa.gov/astromaterials3d/.

Walgreens Boots Alliance is opening robot-powered micro-fulfillment centers across the U.S. to fill customers' prescriptions as the role of stores and pharmacists change. CNBC reports: Inside of a large facility in the Dallas area, they fill thousands of prescriptions for customers who take medications to manage or treat high blood pressure, diabetes or other conditions. Each robot can fill 300 prescriptions in an hour, the company said -- roughly the same number that a typical Walgreens pharmacy with a handful of staff may do in a day.

Walgreens Boots Alliance is opening the automated, centralized hubs to keep up in the fast-changing pharmacy industry. The pandemic has intensified the drugstore chain's need to stay relevant as online pharmacies siphon off sales and more customers have items from toilet paper to toothpaste delivered to their doorstep. The global health crisis has also heightened demand for pharmacists, as hospitals and drugstores hired them to administer Covid vaccines and tests. That has forced Walgreens and its competitors, CVS Health and Rite Aid, to rethink the role of their stores and pharmacists.

By 2025, as much as half of Walgreens' prescription volume from stores could be filled at the automated centers, said Rex Swords, who oversees facilities as Walgreens' group president of centralized services, operations and planning. That will free up more of pharmacists' time to provide health care, Brewer said in an interview with CNBC's Bertha Coombs. "We're doing all of this work, so that the pharmacist has an easier job, so that they can get back to being front and center, building a relationship with that patient and interacting the way they were trained -- the work that they love to do," she said. Pharmacists will continue to fill time-sensitive medications and controlled substances at local stores as the company expands its use of robots.

Sarah Cobey, who studies the interaction of immunity, virus evolution and transmission at the University of Chicago, Jesse Bloom and Tyler Starr, both of whom study virus evolution at Fred Hutchinson Cancer Research Center in Seattle, writing for The New York Times: It's impossible to say whether future variants will have more big Omicron-like jumps or more typical stepwise changes, but we are confident SARS-CoV-2 will continue to evolve to escape immunity. While transmissibility of viruses does plateau at a certain point, other human viruses that escape immunity keep doing so. The influenza vaccine has been updated annually for decades to chase viral evolution, and some influenza viruses show no sign of slowing down. Immune escape is an endless evolutionary arms race, because the immune system can always make new antibodies and the virus has a vast set of mutations to explore in response. For instance, Omicron has just a tiny fraction of the many mutations that have been observed in SARS-CoV-2 or related bat viruses, which are in turn just a small fraction of what lab experiments suggest the virus could potentially explore.

Taking all this together, we expect SARS-CoV-2 will continue to cause new epidemics, but they will increasingly be driven by the ability to skirt the immune system. In this sense, the future may look something like the seasonal flu, where new variants cause waves of cases each year. If this happens, which we expect it will, vaccines may need to be updated regularly similar to the flu vaccines unless we develop broader variant-proof vaccines. And of course, how much all this matters for public health depends on how sick the virus makes us. That is the hardest prediction to make, because evolution selects for viruses that spread well, and whether that makes disease severity go up or down is mostly a matter of luck. But we do know that immunity reduces disease severity even when it doesn't fully block infections and spread, and immunity gained from vaccination and prior infections has helped blunt the impact of the Omicron wave in many countries. Updated or improved vaccines and other measures that slow transmission remain our best strategies for handling an uncertain evolutionary future.

A Nasa astronaut caught a Russian ride back to Earth on Wednesday after a US record 355 days at the International Space Station, returning with two cosmonauts to a world torn apart by war. From a report: Mark Vande Hei landed in a Soyuz capsule in Kazakhstan alongside the Russian Space Agency's Anton Shkaplerov and Pyotr Dubrov, who also spent the past year in space. Despite escalating tensions between the US and Russia over Vladimir Putin's war with Ukraine, Vande Hei's return followed customary procedures. A small Nasa team of doctors and other staff was on hand for the touchdown and planned to return immediately to Houston with the 55-year-old astronaut.

Even before Russia's invasion of Ukraine, Vande Hei said he was avoiding the subject with his two Russian crewmates. Despite getting along "fantastically ... I'm not sure we really want to go there," he said. It was the first taste of gravity for Vande Hei and Dubrov since their Soyuz launch on 9 April last year. Shkaplerov joined them at the orbiting lab in October, escorting a Russian film crew up for a brief stay. To accommodate that visit, Vande Hei and Dubrov doubled the length of their stay. Before departing the space station, Shkaplerov embraced his fellow astronauts as "my space brothers and space sister."

schwit1 shares a report from EurekAlert: A nitrogen doped carbon-coated nickel anode can catalyze an essential reaction in hydrogen fuel cells at a fraction of the cost of the precious metals currently used, Cornell University researchers have found. The new discovery could accelerate the widespread use of hydrogen fuel cells, which hold great promise as efficient, clean energy sources for vehicles and other applications. It's one of a string of discoveries for the Hector D. Abruna lab in their ongoing search for active, inexpensive, durable catalysts for use in alkaline fuel cells.

Recent experiments with nonprecious-metal HOR electrocatalysts needed to overcome two major challenges, the researchers wrote: low intrinsic activity from too strong a hydrogen binding energy, and poor durability due to rapid passivation from metal oxide formation. To overcome these challenges, the researchers designed a nickel-based electrocatalyst with a 2 nanometer shell made of nitrogen-doped carbon. Their hydrogen fuel cell has an anode (where hydrogen is oxidized) catalyst consisting of a solid nickel core surrounded by the carbon shell. When paired with a cobalt-manganese cathode (where oxygen is reduced), the resulting completely precious-metal-free hydrogen fuel cell outputs more than 200 milliwatts per square centimeter.

The presence of nickel oxide species on the surface of the nickel electrode slows the hydrogen oxidation reaction dramatically, Abruna said. The nitrogen-doped carbon coating serves as a protection layer and enhances the HOR kinetics, making the reaction quicker and much more efficient. In addition, the presence of the graphene coating on the nickel electrode prevents the formation of nickel oxides -- resulting in electrodes with dramatically enhanced lifetimes. These electrodes are also much more tolerant to carbon monoxide, which rapidly poisons platinum. The study has been published in the journal Proceedings of the National Academy of Sciences.

InfiniteZero shares a report from Space.com: Last Wednesday (March 23), NASA astronaut Raja Chari and the European Space Agency's Matthias Maurer spent nearly seven hours outside the International Space Station, performing a variety of maintenance work. Amazingly, astrophotographer Sebastian Voltmer managed to capture a snapshot of the spacewalk action from the ground -- and from Maurer's hometown of Sankt Wendel, Germany, no less. "I feel like I just made a once-in-a-lifetime image," Voltmer wrote at SpaceWeather.com, which featured the photo in its online gallery.

Existence of volcanoes makes idea that dwarf planet is inert ball of ice look increasingly improbable. From a report: Strung out in the icy reaches of our solar system, two peaks that tower over the surface of the dwarf planet Pluto have perplexed planetary scientists for years. Some speculated it could be an ice volcano, spewing out not lava but vast quantities of icy slush -- yet no cauldron-like caldera could be seen. Now a full analysis of images and topographical data suggests it is not one ice volcano but a merger of many -- some up to 7,000 metres tall and about 10-150km across. Their discovery has reignited another debate: what could be keeping Pluto warm enough to support volcanic activity? Sitting at the southern edge of a vast heart-shaped ice sheet, these unusual surface features were initially spotted when Nasa's New Horizons spacecraft flew past in July 2015, providing the first close-up images of the icy former planet and its moons.

"We were instantly intrigued by this area because it was so different and striking-looking," said Dr Kelsi Singer, a New Horizons co-investigator and deputy project scientist at Southwest Research Institute in Boulder, Colorado. "There are these giant broad mounds, and then this hummocky-like, undulating texture superimposed on top; and even on top of that there's a smaller bouldery kind of texture." At the time, an ice volcano seemed like the least-weird explanation for these features -- there were no impact craters from asteroids or meteors nearby, suggesting these features had been erased by relatively recent geological events; and no evidence of plate tectonics -- a key contributor to mountain formation on Earth.

SpaceX has ended production of new Crew Dragon astronaut capsules, a company executive told Reuters, as Elon Musk's space transportation company heaps resources on its next-generation spaceship program. From the report: Capping the fleet at four Crew Dragons adds more urgency to the development of the astronaut capsule's eventual successor, Starship, SpaceX's moon and Mars rocket. Starship's debut launch has been delayed for months by engine development hurdles and regulatory reviews. It also poses new challenges as the company learns how to maintain a fleet and quickly fix unexpected problems without holding up a busy schedule of astronaut missions.

"We are finishing our final (capsule), but we still are manufacturing components, because we'll be refurbishing," SpaceX President Gwynne Shotwell told Reuters, confirming the plan to end Crew Dragon manufacturing. She added that SpaceX would retain the capability to build more capsules if a need arises in the future, but contended that "fleet management is key." Musk's business model is underpinned by reusable spacecraft, so it was inevitable the company would cease production at some point. But the timing was not known, nor was his strategy of using the existing fleet for its full backlog of missions. "Crew Dragon has flown five crews of government and private astronauts to space since 2020, when it flew its first pair of NASA astronauts and became the U.S. space agency's primary ride for getting humans to and from the International Space Station," notes Reuters.

An anonymous reader quotes a report from New Atlas: One of the first products made using a novel animal-free egg white is now available in the United States. The unique macarons are the first to be made with an egg white protein that comes from engineered yeast, designed to be indistinguishable from what is found in chicken eggs. The Every Company, founded in 2014 under the name Clara Foods, is one of several food technology companies working to create real animal-free proteins using a method called precision fermentation. The idea behind the process is to break down certain animal products, such as milk and eggs, to their molecular components and then use microorganisms to produce those components. Earlier this year the first cow-free dairy milk using this method hit supermarket shelves in the United States. That product was created using whey proteins from engineered fungus, while other companies are working on similar dairy products using engineered yeast to produce the desired milk proteins.

The Every Company has spent the last few years focusing on using the same technique to produce chicken-free egg whites, working with engineered yeast to produce proteins found in egg whites. The company has not disclosed the specific combination of proteins used to create its final egg white product, however it is likely ovalbumin -- the primary protein component in egg whites -- plays a strong role in the recipe. Arturo Elizondo, CEO of Every Company, said the new egg white product functions exactly like a chicken-derived egg white. It whips, aerates and bakes in ways identical to traditional egg whites, and the company has teamed up with San Francisco-based bakery Chantal Guillon to launch the product in a line of iconic French macarons. The chicken-free egg white is the third animal-free product created by the Every Company. Its first fully commercialized product was an animal-free pepsin, launched in early 2021.

Particles of light called photons can be trapped inside mirrors to form a gas with unusual properties, New Scientist reports. From the report: A gas made of particles of light, or photons, becomes easier to compress the more you squash it. This strange property could prove useful in making highly sensitive sensors. While gases are normally made from atoms or molecules, it is possible to create a gas of photons by trapping them with lasers. But a gas made this way doesn't have a uniform density -- researchers say it isn't homogeneous, or pure -- making it difficult to study properly. Now Julian Schmitt at the University of Bonn, Germany, and his colleagues have made a homogeneous photon gas for the first time by trapping photons between two nanoscale mirrors. They then moved one of the mirrors to measure the compressibility of the photon gas and derive basic properties about it. "We can consider the system to be like an air pump, but it's not filled with air, it's filled with light," says Schmitt. "We compress it and look at how it responds. In this way, we can learn about very fundamental properties." Journal reference: Science, DOI: 10.1126/science.abm2543.

Covid-19 patients who have been hospitalised should also be routinely tested for flu, researchers have said. The call was made after the publication of a paper in the medical journal the Lancet that revealed having both conditions more than doubles the risk of a patient dying. From a report: Scientists also discovered that individuals who had contracted both Sars-CoV-2, the virus that causes Covid-19, and influenza viruses were more than four times more likely to require ventilation support and 2.4 times more likely to die than if they just had Covid-19. "We found that the combination of Covid-19 and flu viruses is particularly dangerous," said Professor Kenneth Baillie of Edinburgh University. "We expect that Covid-19 will circulate with flu, increasing the chance of co-infections. That is why we should change our testing strategy for Covid-19 patients in hospital and test for flu much more widely."

The study looked at more than 305,000 hospitalised patients with Covid-19 and involved researchers from Edinburgh University, Liverpool University, Imperial College London and Leiden University in the Netherlands. A total of 6,965 patients were found to have had Covid-19, while 227 also had the influenza virus. These individuals experienced significantly more severe outcomes, researchers found. "We were surprised that the risk of death more than doubled when people were infected by both flu and Covid-19 viruses," said Professor Calum Semple of Liverpool University. "It is now very important that people get fully vaccinated and boosted against both viruses, and not leave it until it is too late."

On Saturday CNBC published a remarkable headline. "Stem cells may finally offer a cure for Type 1 diabetes." There are 537 million people around the world living with diabetes. And that number is growing.... But over the past 20 years, significant advancements in stem cell research and therapies have revealed promising methods of creating new insulin-making cells, which are needed to cure Type 1 diabetes. Biotech company Vertex Pharmaceuticals recently began a clinical trial where it plans to treat 17 participants who have Type 1 diabetes with new insulin-making cells derived from stem cells. The first patient in the trial, Brian Shelton, has had positive results. After 150 days, Shelton was able to reduce the amount of insulin he injects by 92%.

Other global companies are also working to cure diabetes, such as ViaCyte, CRISPR, and Novo Nordisk, one of the biggest insulin manufacturers in the world.
In CNBC's 20-minute video, a VP/disease area executive from Vertex Pharmaceuticals explains that diabetes is "one of the few diseases where a single cell type is destroyed or missing" — the pancreas cell that produces insulin. So they're exploring "the idea that if you could create those cells and replace them, you can really address the underlying causal biology of the disease directly."

CNBC also spoke to Brian Shelton, the trial's first patient, who's been a Type 1 diabetic for 44 years, and whose pancreas suddenly started producing insulin again. "Now my body does it all on its own," Shelton says. The news was especially surprising, CNBC reports, because "as the first person in the trial, Shelton received only half of the anticipated dose to ensure it was safe."

One researcher they spoke to even predicts that biological solutions will compete with "ongoing efforts to use nanotechnology to miniaturize all the hardware necessary to do this," and that within the next 3 to 5 years patients will finally have the option of "something that is really Cadillac." And Aaron Kowalski, CEO of the nonprofit Juvenile Diabetes Research Foundation, tells CNBC, "I am fully convinced that I will walk away from my insulin pump and continuous glucose monitor in my lifetime, and I would be disappointed if it wasn't in this decade."

CNBC's report concludes, "For diabetics who want a cure that requires no additional treatment, it may no longer be a question of if, but a matter of when."

Science magazine explores how actual scientists feel about Twitter: "I like that there's a low bar to entry [on Twitter] — I can put something out and see how other scientists are thinking of a problem, people who have a different skill set than mine," says biostatistician Natalie Dean of Emory University, whose Twitter account has some 138,000 followers. But the pandemic has also helped demonstrate the limitations of social media. It can be difficult, for example, for scientists to be heard over the cacophony of messages on Twitter — some 500 million each day. And although some scientists have used the platform to elevate their online presence, that has rarely translated into concrete professional rewards....

[A]s the pandemic exploded and researchers sought to pump out information to each other and an eager public, many saw advantages to Twitter. Its vast reach became a draw: more than 200 million active daily users, including an estimated one-quarter of U.S. adults, according to the Pew Research Center. This allows scientists to use a single platform to share research findings with both peers and the public and to foster open discussions... One result is that the platform has carried posts about a majority of the total COVID-19 literature — about 51% of journal articles on pandemic research had been mentioned in at least one tweet through May 2021, according to a report by the Research on Research Institute (RoRI). That exceeds the number cited in scholarly articles or mentioned in several other communications venues, including news stories, Facebook, YouTube, Wikipedia, blogs, and policy documents. And it's well above the level before the pandemic, when studies found that just 10% to 30% of papers on any scientific topic got a mention on Twitter....

But an emerging body of research about tweeting suggests that, overall, scientists often struggle to be heard on social media. One study, for example, found tweets containing links to scholarly papers typically get little engagement. Of 1.1 million such tweets about papers published before the pandemic, half drew no clicks, and an additional 22% attracted just one or two, according to a 2021 paper in the Journal of the Association for Information Science and Technology.
An information scientist at the University of Ottawa tells the magazine that "We are really not at the point where we want to get, which is, ideally, seeing the impact of research on the greater good of society."

Thanks to Slashdot reader sciencehabit for sharing the story...